Navigation Links
Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
Date:3/26/2008

MORRISTOWN, N.J., March 26 /PRNewswire/ -- Vicus Therapeutics, LLC, an oncology-focused, clinical-stage, biopharmaceutical company, announced that Navaneetha K. Rao, Vice President Clinical Research and Development, is scheduled to present at Cambridge Healthtech Institute's 15th International Molecular Medicine Tri-Conference on March 28st at 1:35 p.m. PST at the Mascone North Convention Center in San Francisco. Dr. Rao will focus on considerations that are particularly relevant to successfully executing a Phase 2 multi-center study in India including:

-- Identification and management of clinical research organizations

-- Subject recruitment

-- Principal investigators and site management

-- Project management and communication

-- Quality management

About Vicus Therapeutics

Vicus Therapeutics is a privately-held, biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of cancer supportive care indications with an initial focus on cachexia. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of oral mucositis and cancer fatigue.

For additional information, go to the Company's website: http://www.vicustherapeutics.com.


'/>"/>
SOURCE Vicus Therapeutics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Vicus Therapeutics Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
3. Vicus Therapeutics to Present at the BMO Capital Markets Focus on Healthcare Conference
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... , ... DrugDev believes the only way to achieve real change ... three tenets were on display at the 2nd Annual DrugDev User Summit (hosted by ... and site organizations to discuss innovation and the future of clinical research. , ...
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the Prudential Center in Boston, ... The event, which is held on the United Nations International Day of Persons with ... into the workplace. Suitable Technologies is partnering with NTI to showcase how technology can ...
(Date:12/2/2016)... leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI HIV ... http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton Health ... Self Test to 350 pharmacy representatives in Nairobi and Mombasa, ...
(Date:11/30/2016)... , November 30, 2016 ... a few players hold a dominant share in the ... River Laboratories International, Inc., and Merck KGaA, held a ... 2015. Transparency Market Research observes that these companies are ... on development products that are do not require rabbit ...
Breaking Biology Technology:
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/17/2016)... Nov. 17, 2016 Global Market Watch: ... (Disease-Based Banks, Population-Based Banks and Academics) market is to witness ... Private Biobanks shows the highest Compounded Annual Growth Rate (CAGR) ... region during the analysis period 2014-2020. North America ... 9.95% followed by Europe at 9.56% ...
Breaking Biology News(10 mins):